市场调查报告书
商品编码
1448304
全球乳癌诊断市场规模、份额和成长分析:按类型、应用和产品分类 - 产业预测(2024-2031)Global Breast Cancer Diagnostics Market Size, Share, Growth Analysis, By Type(Imaging, Biopsy), By Application(Screening, Diagnostic and Predictive), By Product(Hospital, Homecare) - Industry Forecast 2024-2031 |
2022年全球乳癌诊断市场规模将为195.1亿美元,从2023年的217.5亿美元扩大到2031年的519.7亿美元,并将在预测期内(2024-2031年)持续成长,预计将以复合年成长率成长11.5%。
乳癌是影响世界各地女性的常见癌症,早期往往没有明显征兆。为了应对这项挑战,乳癌诊断市场正在专注于开发人工智慧技术。例如,Paragon Biosciences LLC 推出了 Qlarity Imaging LLC,以寻求 FDA核准其人工智慧系统,该系统可协助利用放射线诊断乳癌。透过利用人工智慧,该市场的公司旨在显着改善医疗结果。人工智慧正在应用于多种类型的图像,为医院和付款人提供具有成本效益的解决方案。这些公司正在投资具有易于使用的介面和机器学习功能的人工智慧系统,这些系统正在改变乳癌的诊断和治疗方式。全球私人诊断中心的成长是由于对诊断影像的需求不断增长以及公立医院的压力所推动的,而公立医院的诊断影像选择可能有限。FUJIFILM与 Dr. Kutty's Healthcare 合作,在印度班加罗尔开设了 NURA 癌症筛检中心,解决了这个问题。在新兴国家,由于成本高且预算有限,医院在购买诊断影像设备方面面临挑战。一些医院选择翻新产品作为更实惠的选择,价格约为原始成本的 40% 至 60%。看到翻新产品的受欢迎,西门子、GE医疗和飞利浦等产业巨头纷纷推出了推广其使用的计画。这些计划,例如西门子的医疗卓越计划和通用电气医疗集团的金印计划,以较低的价格提供高品质的诊断成像设备,帮助医院满足日益增长的诊断服务需求。
Global Breast Cancer Diagnostics Market size was valued at USD 19.51 billion in 2022 and is poised to grow from USD 21.75 billion in 2023 to USD 51.97 billion by 2031, growing at a CAGR of 11.5% in the forecast period (2024-2031).
Breast cancer is a common type of cancer that affects women worldwide, often showing no clear signs in its early stages. To address this challenge, the breast cancer diagnostics market is focusing on developing AI technologies. Paragon Biosciences LLC, for instance, introduced Qlarity Imaging LLC, aiming to get FDA approval for an AI system to help diagnose breast cancer using radiology. By using AI, companies in this market aim to improve medical outcomes significantly. AI is being used in various types of images, offering hospitals and payers cost-effective solutions. These companies are investing in AI systems with easy-to-use interfaces and machine learning capabilities, changing how breast cancer is diagnosed and cared for. The rise in private diagnostic centers globally is driven by the increasing demand for diagnostic imaging and the pressure on public hospitals, which may have limited imaging options. FUJIFILM Corporation addressed this by launching NURA, a cancer screening center in Bangalore, India, in collaboration with Dr. Kutty's Healthcare. In developing countries, hospitals face challenges in getting diagnostic imaging equipment due to high costs and limited budgets. Some hospitals choose refurbished equipment as a more affordable option, priced at about 40% to 60% of the original cost. Seeing the popularity of refurbished devices, industry leaders like Siemens, GE Healthcare, and Philips have started programs to promote their use. These programs, such as Siemens' Medical Proven Excellence Program and GE Healthcare's Gold Seal Program, offer hospitals quality imaging equipment at lower costs, helping them meet the increasing demand for diagnostic services.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Breast Cancer Diagnostic Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Breast Cancer Diagnostic Market Segmental Analysis
Global Breast Cancer Diagnostic Market is segmented on the basis of application end use and region. By application, the market is segmented into handlings, assembling & disassembling, welding & soldering, clean room, dispensing, processing, others. By end use, market is segmented into automotive, electrical, metal machinery, chemical, rubber & plastics, food, others. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Drivers of the Global Breast Cancer Diagnostic Market
New technologies like advanced imaging methods, molecular diagnostics, and biomarker tests have greatly enhanced how breast cancer is detected and diagnosed. These innovations are leading to the use of more advanced diagnostic tools and helping the market grow.
Restraints in the Global Breast Cancer Diagnostic Market
Liquid biopsies, which involve the analysis of circulating tumor cells and cell-free DNA in blood samples, are gaining traction as non-invasive diagnostic tools for breast cancer. These tests offer potential for early detection and monitoring treatment response.
Market Trends of the Global Breast Cancer Diagnostic Market
Liquid biopsies, which analyze circulating tumor cells and cell-free DNA in blood samples, are becoming more popular as non-invasive ways to diagnose breast cancer. These tests have the potential to find cancer early and keep track of how well treatment is working.